FDA Approves Oral Treatment for Chronic Idiopathic Constipation

Article

The FDA announced the approval of Trulance (plecanatide), Synergy’s once-daily oral treatment for chronic idiopathic constipation (CIC) in adult patients.

The FDA announced the approval of Trulance (plecanatide), Synergy’s once-daily oral treatment for chronic idiopathic constipation (CIC) in adult patients.

Those with CIC experience persistent constipation without structural or biochemical explanation. Trulance works in the upper GI tract to stimulate secretion of intestinal fluid and support regular bowel function.

Trulance’s approval is based on two 12-week, placebo-controlled trials that tested the safety and efficacy of the drug. The trials included 1775 adult participants randomly assigned to receive either a placebo or Trulance, once daily. Participants receiving Trulance were more likely to experience improvement in the frequency of complete spontaneous bowel movements than those receiving placebo, and they also exhibited improvements in stool frequency, consistency, and straining.

The most serious adverse effect associated with Trulance was diarrhea.

Reference

FDA approves Trulance for Chronic Idiopathic Constipation [news release]. FDA website. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm537725.htm. Accessed Jan. 19, 2017.

Related Videos
Image Credit: Adobe Stock - nataliaderiabina
Cholesterol diet and healthy food eating nutritional concept with clean fruits in nutritionist's heart dish and patient's blood sugar control record with diabetic measuring tool | Image Credit: Chinnapong - stock.adobe.com
Image credit: InsideCreativeHouse | stock.adobe.com
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
BillionPhotos.com - stock.adobe.com
Whole psilocybin mushroom in a clear medication capsule | Image credit: Zim - stock.adobe.com
Patient suffering from atopic dermatitis -- Image credit: Nikkikii | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.